Search PubMed⌕ Search

Biomedical subjects

F Barin

Publications and source records attributed to F Barin.

At least 127 records · Page 7Linked to original sources

[Adult T-cell lymphoma/leukemia associated with HTLV-I virus in Martinique: apropos of 2 cases].

Two HTLV-I associated adult T cell leukemia cases were observed in patient from Martinique (French West Indies). These case are similar to the clinical entity, described by Takatsuki in 1977 in Japan and by Catovsky in Caribbean patients, characterized by a lymphadenopathy, skin lesions and visceral involvement, hypercalcemia, an aggressive course, and poor prognosis. The malignant cells with T4 phenotype and often suppressive function, were pleomorphic, mature, with prominent nuclear irregularities. Systematic research of HTLV-I virus or antibodies in patients with this clinical picture, to measure the influence of this virus in T cell lymphoproliferative diseases in France and in French West Indies is required.

Adult↗

Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis.

10 out of 17 (59%) patients with tropical spastic paraparesis (TSP) had antibodies to human T-lymphotropic virus-I (HTLV-I), as did 5 out of 5 TSP patients with systemic symptoms. Only 13 out of 303 (4%) controls, made up of blood donors, medical personnel, and other neurological patients, had such antibodies. These findings suggest either that HTLV-I is neurotropic or that the virus or a related one contributes to the pathogenesis of TSP.

Adolescent↗

Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III.

Antibodies from the serum of patients with the acquired immune deficiency syndrome (AIDS) or with the AIDS-related complex and from the serum of seropositive healthy homosexuals, recognize two major glycoproteins in cells infected with human T-cell lymphotropic virus type III (HTLV III). These glycoproteins, gp160 and gp120, are encoded by the 2.5-kilobase open reading frame located in the 3' end of the HTLV-III genome, as determined by amino terminus sequence analysis of the radiolabeled forms of these proteins. It is hypothesized that gp160 and gp120 represent the major species of virus-encoded envelope gene products for HTLV-III.

Acquired Immunodeficiency Syndrome↗

Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients.

In this study, two glycoproteins (gp160 and gp120) that are encoded by human T-cell lymphoma virus type III (HTLV-III) were the antigens most consistently recognized by antibodies found in patients with the acquired immune deficiency syndrome (AIDS) and with the AIDS-related complex (ARC) and in healthy homosexual males. The techniques used to detect the glycoproteins were radioimmunoprecipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (RIP/SDS-PAGE). Although most antibody-positive samples from ARC patients and from healthy homosexual males also reacted with the virus core protein p24, less than half of the AIDS patients revealed a positive band with p24 under the same conditions. The ability to detect antibodies against a profile of both the major env gene encoded antigens and the gag gene encoded antigens suggests that the RIP/SDS-PAGE may be a valuable confirmatory assay for establishing the presence or absence of antibodies to HTLV-III in human serum samples.

Acquired Immunodeficiency Syndrome↗

Brain membrane disordering after acute in vivo administration of ethanol, isopropanol or t-butanol in rats.

Brain synaptosomal membranes were prepared from rats sacrificed 18 hr after a single intragastric dose of water or of ethanol (100 mmol/kg), when blood ethanol had fallen almost to zero. Fluorescence polarization of DPH, and (Na+ + K+)ATPase activity, were studied in these membranes in the presence of 0, 0.175, 0.3 or 0.7 M ethanol in vitro. After in vivo ethanol, basal ATPase activity was slightly increased, membrane fluidity was unchanged, but both measures showed increased sensitivity to the effects of ethanol in vitro. Similar results were found after an equivalent in vivo dose of isopropanol, but not of t-butanol. These findings indicate that the sensitization to in vitro effects of ethanol or isopropanol, after in vivo treatment with these alcohols, is probably not dependent principally on their lipid solubilities.

1-Propanol↗

Immunogenic effect of hepatitis B vaccine in children: comparison of two- and three-dose protocols.

The immunogenic effect of hepatitis B vaccine was evaluated in 183 seronegative infants from Senegal. Seventy-two seronegative infants received two 5-micrograms doses of vaccine at a two-month interval and 111 seronegative infants received three 5-micrograms doses at one-month intervals. All the children had a booster dose one year after the first injection of vaccine. No difference between the two groups was observed in the seroconversion rate (93.1% and 94.6%, respectively); in the proportion of high anti-HBs titer; or in the anti-HBs geometric mean titer (82 and 92 mIU/ml, respectively). These results demonstrate that two doses of 5 micrograms of hepatitis B vaccine are sufficient in infants to obtain a high immunogenic effect.

Child, Preschool↗

Hepatitis B virus serological markers in Africans with liver cirrhosis and hepatocellular carcinoma.

Serum samples were collected at the time of hospitalization from 221 black Africans suffering from cirrhosis and 453 suffering from hepatocellular carcinoma (HCC). These patients came from Senegal, Burundi and Mali, and 6655 adults from different population groups in these countries were used as controls. Hepatitis B virus (HBV) serum markers, including hepatitis B surface antigen (HBsAg), anti-HBs, antibody to hepatitis B core antigen (anti-HBc), HBeAg and anti-HBe, were determined by radioimmunoassay, while alpha-fetoprotein and complexes between HBsAg and IgM were detected by ELISA tests. HBsAg was detected in 11.8-17.6% of controls as opposed to 63.3% of patients suffering from cirrhosis and 62.7% of patients suffering from HCC. There was less evidence for HBV replication in cirrhosis and HCC in older patients. A significant increase in the frequency of HBsAg/IgM complexes was found in passing from the HBsAg chronic carrier state (13.9%) to cirrhosis (29.9%) and finally to HCC (33.7%).

Adolescent↗

HTLV and immunosuppression.

There is increasing evidence for the link between members of the human T-lymphotropic virus family and clinically important disease. We used indirect membrane immunofluorescence (IMI) to screen patient and control sera for antibodies to human T-cell leukemia virus (HTLV) specific cell membrane antigens (HTLV-MA) of HTLV-I and HTLV-III. Representative sera were screened for antibodies to specific HTLV-encoded proteins using radioimmunoprecipitation (RIP) with SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Essentially all Japanese patients with adult T-cell leukemia/lymphoma (ATLL) from Miyazaki, Japan had detectable antibodies to HTLV-I-MA, further supporting the evidence for the probable etiologic relationship of HTLV-I and ATLL. While 16% of the healthy adults from this endemic region had antibodies to HTLV-I-MA, such antibodies were also found in 42% of the adults hospitalized in Miyazaki with severe infections diseases. Other studies have demonstrated HTLV-I antibodies in 12% of asymptomatic hemophiliacs examined from various U.S. cities. We have previously shown that HTLV-I status positive antibody in hemophiliacs is accompanied by a decrease in the number of T helper cells. Patients seropositive for antibodies to HTLV-I-MA regularly demonstrated antibodies to the env gene encoded gp61 proteins, while lower but significant proportions had antibodies to the gag and lor gene proteins. These and other observations suggest that infection with at least some strains of HTLV-I may be associated with mild or transient immunosuppression, in the absence of leukemia. Analysis by RIP indicated that gp61 and gp45, both encoded by the env gene of HTLV-I, are the most immunogenic proteins of the virus. The gp61 HTLV-I is highly crossreactive with gp67, the major env protein of HTLV-II. Patients with acquired immune deficiency syndrome (AIDS) were also examined for antibodies to HTLV-I-MA and antibodies to the gag, env, and lor gene proteins by RIP. Antibodies were detected in 38-75% of the patients, the higher percentage reflecting the presence of at least one positive sample in those individuals where more than three serial serum samples were tested. Numerous control groups were essentially seronegative for antibodies to HTLV-I proteins. When AIDS patient sera were examined for antibodies to HTLV-III, 95-100% were seropositive. Such antibodies were also found in the majority of asymptomatic Boston-areas hemophiliacs.(ABSTRACT TRUNCATED AT 400 WORDS)

Acquired Immunodeficiency Syndrome↗

Immune response to hepatitis B vaccine in infants and newborns: control trial in an endemic area (Senegal).

In 1978 it was suggested that hepatitis B (HB) vaccine should be used to prevent the early hepatitis B surface antigen (HBsAg) carrier state in children. Immunization was effected by 3 injections of HB vaccine at one-month intervals followed by a booster injection after one year. Children in a control group were immunized with DT-polio vaccine according to the same schedule. The anti-HBs response of the children to HB vaccination was studied in relation to their hepatitis B virus (HBV) serum markers prior to immunization. Of the seronegative children, 70.5% responded to immunization after 2 injections of 5- g doses of HB vaccine and 94% after the third injection. The efficacy of the vaccine was demonstrated by comparison of HB events after one year in 309 seronegative children immunized with HB vaccine and 252 seronegative children immunized with DT-polio vaccine, and after two years in 101 and 119 children, respectively. The incidence of the HBsAg carrier state was reduced by 80% in susceptible children. In order to eliminate the perinatal transmission occurring in newborns with HBsAg-positive mothers, a study of immunization at birth has been instituted. A total of 86 newborns responded to the vaccination as well as older children, irrespective of the HBV status of their mothers. After one year, the incidence of the HBsAg carrier state was reduced by 80%. In Africa, immunization teams have a limited amount of time to devote to each rural community. The immunogenic effect of 2 doses of HB vaccine given at an interval of 2 or 6 months has therefore been investigated. All were given a booster dose one year after the first injection of vaccine. No difference was observed in the seroconversion rate or in the anti-HBs titres as between the two protocols. These results demonstrate that 2 doses of 5 micrograms of HB vaccine are sufficient to obtain a high immunogenic effect in infants. In addition, an investigation was carried out on the immune response to HBsAg and tetanus toxoid antigen when administered simultaneously to children as HB vaccine and DT-polio vaccine. The immune response was at least equal to that observed after administration of these vaccines separately.

Child, Preschool↗

Lack of anti-HBc IgM in neonates with HBsAg carrier mothers argues against transplacental transmission of hepatitis B virus infection.

Transplacental transmission of hepatitis B virus infection was studied in 51 Senegalese neonates born to mothers who were chronic carriers of HBsAg. 13 mothers were positive for both HBsAg and HBeAg. Mother-to-infant transmission of these two markers was different with 3 children being HBsAg positive and HBeAg negative at birth and 6 being HBsAg negative but HBeAg positive. At birth none of the 51 children had anti-HBc IgM detected by a highly specific enzyme immunoassay, indicating that none had had a primary immune response in utero to HBV infection. These HBV serum markers in newborn infants indicate contamination by maternal blood at delivery rather than active infection in utero. Prophylaxis at birth is advisable in children of mothers who are chronic carriers.

Adolescent↗

Brain membrane disordering by administration of a single ethanol dose.

There is a bulk of evidence that ethanol exerts an important direct effect on biological membranes, especially in the central nervous system, during chronic administration. Whether membranes are affected after an acute and subacute ethanol administration remains to be demonstrated. Crude synaptic membrane fluidity (checked by fluorescence polarization) together with (Na+ +K+)ATPase activity were therefore examined 18 hours after a single oral ethanol administration (5 g/kg bwt.) to naive rats or to rats previously intubated with ethanol repeatedly during 4 days (increasing the daily dose from 7 to 10 g/kg). The sensitivity of both parameters to different concentrations of ethanol added in vitro (0.175 M-1.400 M) was also determined. Although no changes in the basal intrinsic fluidity were found, (Na+ +K+)ATPase activity increased slightly after administration of ethanol to naive as well as to short-term ethanol intoxicated rats. The fluidizing as well as the ATPase inhibiting effects following the addition of ethanol in vitro were markedly increased 18 hours after ethanol administration to naive rats. Such an hypersensitization seems not to be related to an unspecific stress or to changes in body temperature and was no longer apparent in short-term ethanol intoxicated rats. Disappearance of the acute ethanol induced hypersensitization with further ethanol administration may represent the first stage of tolerance acquisition.

Animals↗

Hepatitis B vaccine: further studies in children with previously acquired hepatitis B surface antigenemia.

Three doses of inactivated hepatitis B vaccine were given at 1-month intervals to 31 hepatitis B surface antigen (HBsAg)-positive Senegalese children aged between 3 and 24 months. A control group of 18 HBsAg-positive Senegalese children received diphtheria-tetanus-polio vaccine. Immunization of HBsAg-positive infants with hepatitis B vaccine was safe but inefficient. After a 12-month follow-up, the prevalence of HBsAg chronic carriers was not significantly reduced in the hepatitis B vaccine group as compared with the control group: 48.4 and 66.7%, respectively. The presence of hepatitis B antigen was found to be a major risk factor for HBsAg-positive children to develop a chronic carrier state. The risk of developing an HBsAg chronic carrier state was also related to advancing age at time of enrollment in the study.

Carrier State↗

Hepatitis B vaccine: clinical trials in high-risk settings in France. (September 1975-September 1982).

An alum bivalent hepatitis B vaccine containing 5 micrograms/dose of formalin-inactivated and purified HBsAg has been prepared from plasma of HBeAg negative donors. Safety of the product has been controlled by compulsory testing of each batch in susceptible chimpanzees. This vaccine (HB vaccine) was used for the prophylaxis of Hepatitis B in hospital staff working in high-risk settings and patients undergoing periodic dialysis since the Autumn of 1975. Tolerance to the HB vaccine was excellent both in staff and patients as assessed by a nation-side survey on a thousand vaccinees. More than 96% of the staff developed protective levels of anti-HBs after three injections of vaccine given at one month intervals and became fully immune from HBV infection. A booster injection given at one year stimulated an anamnestic rise of anti-HBs sufficient to ensure protective levels of antibody for at least five years post-booster. The response of renal patients varied according to the age of recipients: young patients responded equally as well as the healthy staff, while patients over the sixth decade had a lower and delayed response. Because of that, a fourth injection of HB vaccine was advocated in elderly patients. Dialysis patients who developed anti-HBs either after three or four injections were fully protected against chronic HBV infections. Anti-HBs positive donors who had received a single booster injection of HB vaccine and vaccinees who had received their 12 months booster were both found to be an adequate source of high-titre anti-HBs plasma for preparing hyperimmune anti-HBs globulin. The HB vaccine which is manufactured by Institut Pasteur Production under the name HEVAC B degrees is now used world-wide for the prophylaxis of hospital acquired infection in developed countries and for the prevention of maternal-infant transmission in the endemic countries of Asia and Africa.

Adult↗

Further studies on production and characterization of HBsAg derived from a human hepatoma cell line (PLC/PRF/5).

Four aspects for the use of PLC/PRF/5 cell line as an alternative source of HBsAg for hepatitis B vaccine production were assayed in this study: improvement in HBsAg production with chemical inducers, tests for the presence of hepatitis B virions, antigenic topology of HBsAg polypeptides and immunogenicity of HBsAg in guinea pigs. 10(-6) M dexamethasone and/or 10(-4) M sodium butyrate treatments enhanced HBsAg production by a factor of approximately two when compared with untreated cells. Particles of 35 nm diameter produced by PLC/PRF/5 cells were observed at a CsCl density of 1.22-1.24, associated with typical HBsAg 22 nm spheres. These particles did not contain HBV DNA as proved by negative results of hybridization using cloned HBV/DNA as a probe. Western blot analysis revealed that only polypeptides P 22000 (P1) and P 26000 (P2) were specifically recognized by a human anti-HBs serum, irrespective of the origin of HBsAg, i.e. human serum or PLC/PRF/5 hepatoma cell line. HBsAg purified from PLC/PRF/5 cell line was immunogenic in guinea pigs. However, the humoral response was delayed and lower in terms of anti-HBs titers when compared to the response obtained after immunization with a licensed hepatitis B vaccine (HEVAC B, Institut Pasteur Production).

Animals↗